Delayed antinociceptive effect following morphine-6-glucuronide administration in the rat - pharmacokinetic/pharmacodynamic modelling

Pain

Volumn 74, Issue 2-3, 1998, Pages 287-296

  Gårdmark, Marie ^a   Hammarlund Udenaes, Margareta ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

Antinociceptive effect; Effect delay; Morphine 6 glucuronide; Pharmacodynamic modelling; Pharmacokinetics

Indexed keywords

MORPHINE 6 GLUCURONIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINOCICEPTION; ARTICLE; BOLUS INJECTION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG INFUSION; DRUG POTENCY; DRUG TOLERANCE; ELECTROSTIMULATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; METHODOLOGY; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; RAT;

EID: 0345310067     PISSN: 03043959     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3959(97)00180-2     Document Type: Article

References (52)

1. Aasmundstad T.A., Mørland J., Paulsen R.E. Distribution of morphine-6-glucuronide and morphine across the blood-brain barrier in awake, freely moving rats investigated by in vivo microdialysis. J. Pharmacol. Exp. Ther. 275:1995;435-441.
2. Abbott F., Palmour M. Morphine-6-glucuronide: analgesic effects and receptor binding profile in rats. Life Sci. 43:1988;1685-1695.
3. Barjavel M.J., Scherrmann J.-M., Bhargava H.N. Relationship between morphine analgesia and cortical extracellular fluid levels of morphine and its metabolites in the rat: a microdialysis study. Br. J. Pharmacol. 116:1995;3205-3210.
4. Beal, S.L. and Sheiner, L.B., NONMEM Users' Guides, NONMEM Project Group, University of California at San Fransisco, San Fransisco, 1992.
5. Bodd E., Jacobsen D., Lund E., Ripel A., Morland J., Wiik L.E. Morphine-6-glucuronide might mediate the prolonged opioid effect of morphine in acute renal failure. Hum. Exp. Toxicol. 9:1990;317-321.
6. Carroll M.N., Lim R.K.S. Observation on the neuropharmacology of morphine and morphine-like analgesia. Arch. Int. Pharmacodyn. Ther. 125:1960;383-403.
7. Carrupt P.-A., Testa B., Bechalany A., El Tayar N., Descas P., Perrisoud D. Morphine 6-glucuronide and morphine 3-glucuronide as molecular chameleons with unexpected lipophilicity. J. Med. Chem. 34:1991;1272-1275.
8. Cox, E.H., Pharmacology of μ-opioid receptor agonists: need for preclinical in vivo pharmacodynamic investigations, Thesis, University of Leiden, 1997.
9. Dahlström B.E., Paalzow L.K. Pharmacokinetics of morphine in plasma and discrete areas of the rat brain. J. Pharmacokinet. Biopharm. 3:1975;293-302.
10. Dayneka N.L., Garg V., Jusko W.J. Comparison of four basic models of indirect pharmacodynamic responses. J. Pharmacokinet. Biopharm. 21:1993;457-478.
11. Ekblom, M., Gårdmark, M. and Hammarlund-Udenaes, M., Pharmacokinetics and pharmacodynamics of morphine-3-glucuronide in rats and its influence on the antinociceptive effect of morphine, Biopharm. Drug Dispos., 14 (1993a) 1-11.
12. Ekblom, M., Hammarlund-Udenaes, M. and Paalzow, L., Tolerance development and rebound effects of morphine in relation to different administrations in rats, J. Pharmacol. Exp. Ther., 266 (1993b) 244-252.
13. Faura C.C., Olaso M.J., Garcia C.C., Horga J.F. Lack of morphine-6-glucuronide antinociception after morphine treatment. Is morphine-3-glucuronide involved? Pain. 65:1996;25-30.
14. Frances B., Gout R., Monsarrat B., Cros J., Zajac J.M. Further evidence that morphine-6 beta-glucuronide is a more potent opioid agonist than morphine. J. Pharmacol. Exp. Ther. 262:1992;25-31.
15. Gaillard P., Carrupt P.-A., Testa B. The conformation-dependent lipophilicity of morphine glucuronides as calculated from their molecular lipophilicity potential. Bioorg. Med. Chem. Lett. 4:1994;737-742.
16. Gong Q., Hedner T., Hedner J., Björkman R., Nordberg G. Antinociceptive and ventilatory effects of the morphine metabolites: morphine-6-glucuronide and morphine-3-glucuronide. Eur. J. Pharmacol. 193:1991;47-53.
17. Gårdmark M., Ekblom M., Bouw R., Hammalund-Udenaes M. Quantification of effect delay and acute tolerance development to morphine in the rat. J. Pharmacol. Exp. Ther. 267:1993;1061-1067.
18. Hammarlund-Udenaes M., Paalzow L.K., de Lange E.C.M. Drug equilibration across the blood-brain barrier - pharmacokinetic considerations based on the microdialysis method. Pharm. Res. 14:1997;128-134.
19. Hanna M.H., Peat S.J., Woodham M., Knibb A., Fung C. Analgesic efficacy and CSF pharmacokinetics of intrathecal morphine-6-glucuronide: comparison with morphine. Br. J. Anaesth. 64:1990;547-550.
20. Hasselström J., Svensson J.O., Säwe J., Wiesenfeld-Hallin Z., Yue Q.-Y., Xu X.-J. Disposition and analgesic effects of systemic morphine, morphine-6-glucuronide and normorphine in rat. Pharmacol. Toxicol. 79:1996;40-46.
21. Hucks D., Thompson P., McLoughlin L., Joel S., Patel N., Grossman A., Rees L., Slevin M. Explanation at the opioid receptor level for differing toxicity of morphine and morphine-6-glucuronidation. Br. J. Cancer. 65:1992;122-126.
22. Igawa Y., Westerling D., Mattiasson A., Andersson K.E. Effects of morphine metabolites on micturition in normal, unanaesthetized rats. Br. J. Pharmacol. 110:1993;257-262.
23. Joel S.P., Osborne R.J., Slevin M.L. An improved method for the simultaneous determination of morphine and its principal glucuronide metabolites. J. Chromatogr. 430:1988;394-399.
24. Johnson S.M., Fleming W.F. Mechanism of cellular adaptive sensitivity changes: application to opioid tolerance and dependence. Pharmacol. Rev. 41:1989;435-488.
25. Jonsson, N. and Karlsson, M.O., Manual of Xpose, Faculty of Pharmacy, Uppsala University, http://www.biof.uu.se/xpose, 1996.
26. Jurna I., Baldauf J., Fleischer W. Depression by morphine-6-glucuronide of nociceptive activity in rat thalamus neurons: comparison with morphine. Brain Res. 722:1996;132-138.
27. Jusko W.J., Ko H.C. Physiologic indirect response models characterize diverse types of pharmacodynamic effects. Clin. Pharmacol. Ther. 56:1994;406-419.
28. Ling G.S.L., Spiegel K., Lockhart S.H., Pasternak G.W. Separation of opioid analgesia from respiratory depression: evidence for different receptor mechanisms. J. Pharmacol. Exp. Ther. 232:1985;149-155.
29. Mandema J.W., Wada D.R. Pharmacodynamic model for acute tolerance development to the electroencephalographic effects of alfentanil in the rat. J. Pharmacol. Exp. Ther. 275:1995;1185-1194.
30. Murphey L.J., Olsen G.D. Morphine-6-beta-D-glucuronide respiratory pharmacodynamics in the neonatal guinea pig. J. Pharmacol. Exp. Ther. 268:1994;110-116.
31. Osborne R.J., Joel S.P., Slevin M.L. Morphine intoxication in renal failure: the role of morphine-6-glucuronide. Br. Med. J. 292:1986;1548-1549.
32. Osborne R., Joel S., Trew D., Slevin M. Analgesic activity of morphine-6-glucuronide. Lancet. i:1988;828.
33. Osborne R., Thompson P., Joel S., Trew D., Patel N., Slevin M. The analgesic activity of morphine-6-glucuronide. Br. J. Clin. Pharmacol. 34:1992;130-138.
34. Ouellet D.M.-C., Pollack G.M. A pharmacokinetic-pharmacodynamic model of tolerance to morphine analgesia during infusion in rats. J. Pharmacokin. Biopharm. 23:1995;531-549.
35. Paalzow G., Paalzow L. The effects of caffeine and theophylline on nociceptive stimulation in the rat. Acta Pharmacol. Toxicol. 32:1973;22-32.
36. Pasternak G.W., Bodnar R.J., Clark J.A., Inturrisi C.E. Morphine-6-glucuronide, a potent mu agonist. Life Sci. 41:1987;2845-2849.
37. Paul D., Standifer K., Inturrisi C., Pasternak G. Pharmacological characterization of morphine-6β-glucuronide, a very potent morphine metabolite. J. Pharmacol. Exp. Ther. 251:1989;477-483.
38. Peat S.J., Hanna M.H., Woodham M., Knibb A.A., Ponte J. Morphine-6-glucuronide: effects on ventilation in normal volunteers. Pain. 45:1991;101-104.
39. Pelligrino D., Riegler F., Albrecht R. Ventilatory effects of fourth cerebroventricular infusions of morphine-6- or morphine-3-glucuronide in the awake dog. Anesthesiology. 71:1989;936-940.
40. Porchet H.C., Benowitz N.L., Sheiner L.B. Pharmacodynamic model of tolerance: application to nicotine. J. Pharmacol. Exp. Ther. 244:1988;231-236.
41. Portenoy R., Thaler H., Inturrisi C., Friedlander-Klar H., Foley K. The metabolite morphine-6-glucuronide contributes to the analgesia produced by morphine infusion in patients with pain and normal renal function. Clin. Pharm. Ther. 51:1992;422-431.
42. Shafer S.L., Siegel L.C., Cooke J.E., Scott J.C. Testing computer-controlled infusion pumps by simulation. Anesthesiology. 68:1988;261-266.
43. Shafer S.L., Varvel J.R., Aziz N., Scott J.C. Pharmacokinetics of fentanyl administrated by computer-controlled infusion pump. Anesthesiology. 73:1990;1091-1102.
44. Sheiner L.B., Verotta D. Further notes on physiologic indirect response models. Clin. Pharmacol. Ther. 58:1995;238-240.
45. Sheiner L.B., Stanski D.R., Vozeh S., Miller R.D., Ham J. Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine. Clin. Pharmacol. Ther. 25:1979;358-371.
46. Shimomura K., Kamata O., Ueki S., Ida S., Oguri K., Yoshimura H., Tsukamoto H. Analgesic effect of morphine glucuronides. Tohoku J. Exp. Med. 105:1971;45-52.
47. Stain F., Barjavel M.J., Sandouk P., Plotkine M., Scherrmann J.M., Bhargava H.N. Analgesic response and plasma and brain extracellular fluid pharmacokinetics of morphine and morphine-6-beta-D-glucuronide in the rat. J. Pharmacol. Exp. Ther. 274:1995;852-857.
48. Sullivan A., McQuay H., Bailey D., Dickenson A. The spinal antinociceptive actions of morphine metabolites morphine-6-glucuronide and normorphine in the rat. Brain Res. 482:1989;219-224.
49. Thompson P.I., Joel S.P., John L., Wedzicha J.A., Maclean M., Slevin M.L. Respiratory depression following morphine and morphine-6-glucuronide in normal subjects. Br. J. Clin. Pharmacol. 40:1995;145-152.
50. Uchihashi Y., Kuribara H., Morita T., Kitani Y., Karasawa F., Sato T. Differential effects of morphine-6-glucuronide, an active metabolite of morphine, and morphine on locomotor activity in mice: involvement of the opioid receptor. Pharmacol. Toxicol. 78:1996;322-326.
51. Van der Graaf, P.H., Van Schaick, E.A., Mahôt, R.A.A., Ijzerman, A.P. and Danhof, M., Mechanism-based modelling of drug-receptor interactions in vivo: a population approach, Conference on the population approach: measuring and managing variability in response, concentration and dose, Geneve, 1997.
52. Yoshimura H., Ida S., Oguri K., Tsukamoto H. Biochemical basis for analgesic activity of morphine-6-glucuronide-1. Biochem. Pharmacol. 22:1973;1423-1430.